asco 2018 - tarceva combined with carboplatin & alimta - given upfront - affect pace of disease?
Published 5 years ago • 188 plays • Length 6:27Download video MP4
Download video MP3
Similar videos
-
11:29
asco 2018 keynote189 - cisplatin or carboplatin with alimta & keytruda - practice changing approach?
-
9:11
asco 2018 - tarceva or tarceva with avastin as 1st line for egfr pos. nsclc vs. tagrisso or vizimpro
-
12:26
asco 2018 - potential showdown of two positive trials? keynote 407 and impower 131
-
7:54
keytruda combined with anti-vegf treatment:use in patients with advanced nsclc-asco lung review 2022
-
4:26
asco 2018 - dream study - chemo with imfinzi (durvalumab) for mesothelioma
-
9:40
asco 2018 - checkmate 227 - combinations of nivolumab and ipilimumab, or nivolumab and and chemo
-
2:52
asco 2018 - combining metformin with standard egfr therapy - is the jury still out
-
7:35
asco 2018 - will taking mod to high dose steroids affect lung cancer pts on immunotherapy?
-
3:36
gracecastuc-018_radiation_safely combine tarceva with brain radiation for lc brain metastases?
-
3:34
asco 2018 - keynote 158 - keytruda in previously treated, now relapsing patients with sclc
-
12:15
asco 2018 head and neck roundtable attempts to decrease toxicity of chemoradiotherapy
-
11:15
asco 2018 - keynote 042 - keytruda as a single agent compared to doublet chemotherapy for nsclc
-
9:16
asco 2018 head and neck roundtable advances in immunotherapy in head and neck cancer
-
11:58
asco lung cancer roundtable - mesothelioma updates
-
4:51
gracecast-116_lung-cancer_asco 2012 lc highlights: dr. neal on select trial of tarceva (erlotinib)
-
7:45
asco 2021 lung recap: carbo/pemetrexed/pembro and acquired resistance in egfrm or alk nsclc
-
5:46
patritumab deruxtecan: use in previously treated patients without mutations - asco lung review 2022
-
4:42
asco lung cancer roundtable - new combinations chemo immunotherapy for extensive stage sclc